Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.

Cancer medicine - 1 Mar 2016

Nitta Yusuke, Shimizu Saki, Shishido-Hara Yukiko, Suzuki Kaori, Shiokawa Yoshiaki, Nagane Motoo

Abstract excerpt

A mutant form of epidermal growth factor receptor (EGFR), EGFRvIII, is common in glioblastoma (GBM) and confers enhanced tumorigenic activity and drug resistance. Nimotuzumab, an anti-EGFR antibody, has shown preclinical and clinical activity to GBM, but its specific activity against EGFRvIII has not been fully investigated. Human glioma U87MG or LNZ308 cells overexpressing either wild-type (wt) EGFR or EGFRvIII...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Drug Synergism

Share to Glioma

Share to Temozolomide

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26778701
DOI: 10.1002/cam4.614
PMCID: PMC4799951

Genes

EGFR
MGMT
MLH1
MSH6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.PMID 26778701Read ↗

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.Semantic proximity Read ↗

EGFR-Driven Phenotypes Dictate Differential Therapeutic Response to Radiotherapy and Temozolomide in GlioblastomaSemantic proximity Read ↗

Expression and pharmacological inhibition of TrkB and EGFR in glioblastomaSemantic proximity Read ↗

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Semantic proximity Read ↗

[Monoclonal antibodies in high-grade gliomas].Semantic proximity Read ↗

Expression of EGFRvIII in Glioblastoma: Prognostic Significance RevisitedSemantic proximity Read ↗

A combination of IFN-β and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulationSemantic proximity Read ↗

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.Semantic proximity Read ↗

Minimally Cytotoxic Doses of Temozolomide Produce Radiosensitization in Human Glioblastoma Cells Regardless of MGMT ExpressionSemantic proximity Read ↗

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.Semantic proximity Read ↗

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read ↗

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.